18F-PSMA-1007的使用和PET/MR在前列腺癌诊断中的作用还没有达成定论。有报道表明使用18F-PSMA-1007和PET/MR技术在前列腺癌复发方面存在潜在的优势和劣势，但尚未被包括在EAU指南中。本研究的目的是评估18F-PSMA-1007 PET/MR在检测PSA水平极低（<0.5 ng/mL）的BCR病灶方面的有效性。本前瞻性研究纳入了60例经过根治性前列腺切除术（RP）后发生BCR的患者，其PSA范围为0.1-0.5 ng/mL。所有患者均接受了整体和盆腔18F-PSMA-1007 PET/MR检查，并通过12个月的随访进行了验证。共检测到45名患者中的53个病灶，检出率为75%。平均PSA值为0.31 ng/mL。在所有PSMA阳性的灶中，91%位于盆腔，只有9%位于盆腔外。有29%的患者检测出了局部复发病灶，64%的患者检测出了PSMA阳性淋巴结，7%的患者检测出了骨转移病灶。在PSA水平极低的早期BCR患者中，18F-PSMA-1007 PET/MR似乎是一种优秀的诊断工具，特别是在dt PSA < 6个月的情况下。结合18F-PSMA-1007和整体PET/MR以及精确的多参数评估盆腔病灶的协同效应对早期BCR患者特别有益。

The use of 18F-PSMA-1007 and the role of PET/MR in the diagnosis of prostate cancer are not conclusively confirmed. There are reports indicating the potential pros and cons of using 18F-PSMA-1007 as well as the PET/MR technique in prostate cancer recurrence, but they are not yet included in the EAU guidelines. The aim of the study was to assess the effectiveness of 18F-PSMA-1007 PET/MR in detecting BCR lesions at very low PSA levels <0.5 ng/mL.Sixty patients with BCR after radical prostatectomy (RP) with PSA ranged 0.1-0.5 ng/mL were enrolled in a prospective study. All patients underwent simultaneous whole-body and pelvic 18F-PSMA-1007 PET/MR. The obtained results were verified by 12-month follow-up.Fifty-three lesions were detected in 45 patients with 75% detection rate. The mean PSA value was 0.31 ng/mL. Of all PSMA-positive foci, 91% were localized in the pelvis, and only 9% of lesions were located in the extrapelvic region. Local recurrences were detected in 29%, PSMA-positive lymph nodes were detected in 64% of patients and bone metastases lesions were detected in 7% of patients.18F-PSMA-1007 PET/MR seems to be an excellent diagnostic tool in patients with early BCR with very low PSA levels, especially with dt PSA < 6 months. The synergistic effect of combining 18F-PSMA-1007 and whole-body PET/MR with precise multiparametric assessment of pelvic lesions is of particular benefit in early BCR.